"10.1371_journal.pone.0102034","plos one","2014-09-09T00:00:00Z","Jeremias Motte; Florian Alten; Carina Ewering; Nani Osada; Ella M Kadas; Alexander U Brandt; Timm Oberwahrenbrock; Christoph R Clemens; Nicole Eter; Friedemann Paul; Martin Marziniak","Department of Neurology, University of Muenster Medical Center, Muenster, Germany; Department of Ophthalmology, University of Muenster Medical Center, Muenster, Germany; NeuroCure Clinical Research Center and Experimental and Clinical Research Center, Charité University Medicine Berlin and Max Delbrück Center for Molecular Medicine, Berlin, Germany; Department of Neurology, Charité University Medicine Berlin, Berlin, Germany; Department of Neurology, Isar-Amper-Klinikum, Haar, Germany; Institution of Medical Informatics, University of Muenster, Muenster, Germany","Conceived and designed the experiments: JM FA CE NO EMK CRC FP MM. Performed the experiments: JM FA CE EMK AB TO CRC FP MM. Analyzed the data: JM FA CE NO EMK AB TO CRC NE MM. Contributed reagents/materials/analysis tools: JM FA CE NO EMK AB TO NE FP MM. Wrote the paper: JM FA CE NO EMK AB TO CRC NE FP MM.","The author disclosure information is as follows: Motte J, none; Alten F, Heidelberg Engineering, Novartis, Bayer, Allergan; Ewering C, none; Osada N, none; Kadas EM, none; Brand A, none; Oberwahrenbrock T, none; Clemens CR, Heidelberg Engineering, Novartis, Bayer, Allergan; Eter N, Heidelberg Engineering, Bayer, Novartis, Allergan, Pfizer, Bausch and Lomb; Paul F, BiogenIdec, Teva, SanofiGenzyme, Merck, Novartis, Heidelberg Engineering; supported by German Research Foundation (DFG Exc 257), German Ministry for Education and Research (BMBF Competence Network Multiple Sclerosis); and Marziniak M, BiogenIdec, Teva, SanofiGenzyme, Merck, Novartis. The authors confirm that they received funding from Novartis Germany but this does not alter their adherence to all PLOS ONE policies on sharing data and materials.","2014","09","Jeremias Motte","JM",11,TRUE,8,9,10,11,TRUE,TRUE,FALSE,0,NA,FALSE
